ORGANIZATION AND NATURE OF OPERATIONS	9 Months Ended
Dec. 31, 2021
ORGANIZATION AND NATURE OF OPERATIONS
ORGANIZATION AND NATURE OF OPERATIONS	NOTE 1 – ORGANIZATION AND NATURE OF OPERATIONS Nascent Biotech, Inc. (“Nascent” or the “Company”) was incorporated on March 3, 2014, under the laws of the State of Nevada. The Company is actively developing Pritumumab for the treatment of brain cancer and pancreatic cancer. Nascent is also actively researching other cancers that have a high probability of benefiting from the therapeutic effects of Pritumumab because they share a common target. Pritumumab has shown to be very effective at low doses in previous clinical studies in Japan. Nascent is a Phase 1 clinical stage biopharmaceutical company that focuses on biologic drug candidates that are being clinical tested for the treatment of brain and pancreatic cancer. On March 31, 2017, the Company filed its IND submission with the United States Food and Drug Administration (FDA) for clearance to begin Phase I clinical trials. On December 7, 2018, the Company received a letter from the FDA allowing it to use a specific lot of drug substance to begin phase 1 clinical trial. On March 15, 2021, the Company opened phase one clinical trials. The trial is a dose escalation trial to determine toxicity levels of the drug with patients. As of December 31, 2021, the trials are open to the third cohort of patients with the dose escalation to 8.0mg/kg. Phase 1 of the trial will complete after the fourth cohort with dosage of 12mg/kg is completed. After its completion, the data will be submitted to the FDA for approval to commence phase 2 of the clinical trial studies.

ORGANIZATION AND NATURE OF OPERATIONS

9 Months Ended

Dec. 31, 2021

ORGANIZATION AND NATURE OF OPERATIONS

NOTE 1 – ORGANIZATION AND NATURE OF OPERATIONS

Nascent Biotech, Inc. (“Nascent” or the “Company”) was incorporated on March 3, 2014, under the laws of the State of Nevada. The Company is actively developing Pritumumab for the treatment of brain cancer and pancreatic cancer. Nascent is also actively researching other cancers that have a high probability of benefiting from the therapeutic effects of Pritumumab because they share a common target. Pritumumab has shown to be very effective at low doses in previous clinical studies in Japan. Nascent is a Phase 1 clinical stage biopharmaceutical company that focuses on biologic drug candidates that are being clinical tested for the treatment of brain and pancreatic cancer.

On March 31, 2017, the Company filed its IND submission with the United States Food and Drug Administration (FDA) for clearance to begin Phase I clinical trials. On December 7, 2018, the Company received a letter from the FDA allowing it to use a specific lot of drug substance to begin phase 1 clinical trial. On March 15, 2021, the Company opened phase one clinical trials. The trial is a dose escalation trial to determine toxicity levels of the drug with patients. As of December 31, 2021, the trials are open to the third cohort of patients with the dose escalation to 8.0mg/kg. Phase 1 of the trial will complete after the fourth cohort with dosage of 12mg/kg is completed. After its completion, the data will be submitted to the FDA for approval to commence phase 2 of the clinical trial studies.